A phase I study of alefacept (AmeviveTM) in the treatment of cutaneous T-cell lymphoma and peripheral T-cell NHL
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Alefacept (Primary)
- Indications Peripheral T-cell lymphoma; T cell lymphoma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 11 Aug 2017 Status changed from active, no longer recruiting to completed.
- 24 Jun 2015 Planned End Date changed from 1 May 2015 to 1 May 2018 as reported by ClinicalTrials.gov record.